Table 1B: Patient demographic and tumor characteristics in the serum cohort.
Total (n = 46) | Short-Term Survivors (n = 25) | Long-Term Survivors (n = 21) | p-value | |
---|---|---|---|---|
Age | 56 (26–78) | 56 (26–78) | 56 (36–73) | 0.834 |
Male | 31 (67) | 17 (68) | 14 (67) | 1.000 |
CRC Location | ||||
Colon | 39 (85) | 22 (88) | 17 (81) | 0.686 |
Rectum | 7 (15) | 3 (12) | 4 (19) | |
CRC Nodes | ||||
Negative | 14 (30) | 5 (20) | 9 (43) | 0.117 |
Positive | 32 (70) | 20 (80) | 12 (57) | |
CRC TNM Stage at Presentation | ||||
I | 6 (13) | 0 (0) | 6 (29) | 0.009 |
II | 2 (4) | 1 (4) | 1 (5) | |
III | 10 (22) | 5 (20) | 5 (24) | |
IV | 28 (61) | 19 (76) | 9 (43) | |
CEA | ||||
< 200 ng/mL | 40 (87) | 20 (80) | 20 (95) | 0.114 |
≥ 200 ng/mL | 4 (9) | 4 (16) | 0 (0) | |
Disease Free Interval | ||||
< 12 months | 36 (78) | 21 (84) | 15 (71) | 0.475 |
≥ 12 months | 10 (22) | 4 (16) | 6 (29) | |
CRLM Diagnosis | ||||
Synchronous | 27 (59) | 19 (76) | 8 (38) | 0.016 |
Metachronous | 19 (41) | 6 (24) | 13 (62) | |
CRLM Largest Size | ||||
< 5 cm | 32 (70) | 15 (60) | 17 (81) | 0.199 |
≥ 5 cm | 14 (30) | 10 (40) | 4 (19) | |
CRLM Numbers | ||||
Single | 14 (30) | 5 (20) | 9 (43) | 0.117 |
Multiple | 32 (70) | 20 (80) | 12 (57) | |
CRLM Differentiation | ||||
Moderate | 37 (80) | 18 (72) | 19 (90) | 0.111 |
Poor | 4 (9) | 4 (16) | 0 (0) | |
CRLM Resectability | ||||
R0 | 29 (63) | 13 (52) | 16 (76) | 0.236 |
R1 | 6 (13) | 4 (16) | 2 (10) | |
R2 | 11 (24) | 8 (32) | 3 (14) | |
Clinical Risk Score | ||||
0–2 Low Risk | 18 (39) | 5 (20) | 13 (62) | 0.006 |
3–5 High Risk | 28 (61) | 20 (80) | 8 (38) | |
Chemotherapy | ||||
Pre-CRLM Resection | 36 (78) | 25 (100) | 11 (52) | < 0.001 |
Post-CRLM Resection | ||||
Systemic only | 18 (39) | 8 (32) | 10 (48) | 0.423 |
Systemic + HAIP | 26 (57) | 15 (60) | 11 (52) | |
KRAS | ||||
Mutant | 15 (33) | 12 (48) | 3 (14) | 0.037 |
Wild Type | 28 (61) | 12 (48) | 16 (76) | |
BRAF V600E | ||||
Mutant | 0 (0) | 0 (0) | 0 (0) | − |
Wild type | 31 (67) | 16 (64) | 15 (71) |
Abbreviations: CRC, colorectal cancer; CRLM, colorectal liver metastasis; TNM, tumor node metastasis, CEA, carcinoembryonic antigen. HAIP, hepatic artery infusion pump.